Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress

Jaguar continues its sharp strategic focus on its global development program for crofelemer for rare-disease intestinal ...
FiercePharma

Napo Terminates Glenmark Pharmaceuticals for Failure to Commercially Develop Crofelemer

SAN FRANCISCO--(BUSINESS WIRE)--Napo Pharmaceuticals, Inc. ("Napo") announced today that it has terminated its Collaboration Agreement with Glenmark Pharmaceuticals Ltd. ("Glenmark"), dated July 2, ...
Yahoo Finance

Napo Pharmaceuticals Supports Groundbreaking Study on Quality of Life for Cancer Patients and Survivors

SAN FRANCISCO, CA / ACCESSWIRE / September 26, 2023 / In an effort to shed light on the diverse and profound challenges faced by individuals living with a diagnosis or a history of cancer, Napo ...
FierceBiotech

Napo Pharmaceuticals, Inc. Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera

SAN FRANCISCO, Sept. 22 /PRNewswire/ -- Napo Pharmaceuticals today announces positive clinical data on the effectiveness of crofelemer from a study for CRO-ID in treating severely ill cholera patients ...
FierceBiotech

Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea

SOUTH SAN FRANCISCO, Calif., April 10 /PRNewswire/ -- Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU) is pleased to announce the positive results of a successfully completed Phase 2 trial for CRO-ID ...